Petros Pharmaceuticals Announces Closing of $7.5 Million Offering
Petros Pharmaceuticals (Nasdaq: PTPI) has successfully closed a registered direct offering and private placement, raising approximately $7.5 million. The funds will support the expansion of its men's health platform and provide working capital. This capital boost marks the company's strongest cash position to date, enhancing their strategic plans in the men's health category. Katalyst Securities LLC acted as the financial advisor for this transaction. Petros aims to lead the market by developing innovative therapeutics for issues such as erectile dysfunction and Peyronie's disease.
- Raised approximately $7.5 million from direct offering and private placement.
- Achieved the strongest cash position in company history.
- Plans for expansion in the men's health platform.
- Ongoing support from the largest investor indicates confidence.
- Dependence on a single product, Stendra®, may pose risks.
- Company's history of significant losses raises concerns.
- Potential risks from emerging market conditions and regulatory approvals.
NEW YORK, Dec. 28, 2021 Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced the closing of its previously announced registered direct offering and private placement with the company's largest investor and other existing investors for gross proceeds of approximately
Katalyst Securities LLC acted as financial advisor to Petros Pharmaceuticals with respect to this transaction.
"This latest raise, in which we are grateful that our largest stockholder continues to participate, creates our strongest cash position in the history of the Company going into 2022, which we believe to be a vital component in our strategic plans toward leadership in the men's health category and allows us considerable flexibility and confidence in our ability to execute on that strategy," commented Fady Boctor, Petros Pharmaceuticals' President and Chief Commercial Officer.
ABOUT PETROS PHARMACEUTICALS
Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men's health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including, but not limited to erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie's disease, hormone health and substance use disorders.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans", " expects" or "does not expect", "proposed", "is expected", "budgets", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future, such as statements related to the intended use of proceeds from the offering. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, Petros Pharmaceuticals' ability to execute on its business strategy, including its plans to develop and commercialize its product candidates; Petros Pharmaceuticals' ability to comply with obligations as a public reporting company; the ability of Petros Pharmaceuticals to timely and effectively implement controls and procedures required by Section 404 of the Sarbanes-Oxley Act of 2002; the risk that the financial performance of Petros Pharmaceuticals may not be as anticipated by the merger transactions that resulted in Petros Pharmaceuticals' creation; risks resulting from Petros Pharmaceuticals' status as an emerging growth company, including that reduced disclosure requirements may make shares of Petros Pharmaceuticals common stock less attractive to investors; risks related to Petros Pharmaceuticals' history of incurring significant losses; risks related to Petros Pharmaceuticals' dependence on the commercialization of a single product, Stendra®, and on a single distributor thereof; risks related to Petros Pharmaceuticals' ability to obtain sufficient quantities of Stendra® in a timely manner or on commercially viable terms; risks related to Petros Pharmaceuticals' ability to obtain regulatory approvals for, or market acceptance of, any of its products or product candidates; and the expected or potential impact of the novel coronavirus pandemic, including the emergence of new variants, such as the Delta variant, and the related responses of governments, consumers, customers, suppliers, employees and Petros Pharmaceuticals, on Petros Pharmaceuticals' business, operations, employees, financial condition and results of operations. A discussion of these and other factors, including risks and uncertainties with respect to Petros Pharmaceuticals, and other factors described in Petros Pharmaceuticals' most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the Securities and Exchange Commission, which can be reviewed at www.sec.gov. Petros Pharmaceuticals disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
View original content:https://www.prnewswire.com/news-releases/petros-pharmaceuticals-announces-closing-of-7-5-million-offering-301451098.html
SOURCE Petros Pharmaceuticals, Inc.
FAQ
What is the recent capital raise by Petros Pharmaceuticals (PTPI)?
What will Petros Pharmaceuticals do with the proceeds from the offering?
How does the latest funding impact Petros Pharmaceuticals (PTPI)?
What are the risks associated with Petros Pharmaceuticals (PTPI)?
